HEMA-Lysine-Based Cryogels for Highly Selective Heparin Neutralization.

Area of Science:

• Biomaterials Science
• Polymer Chemistry
• Biomedical Engineering

Background:

• Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are crucial anticoagulants in medical procedures, necessitating effective neutralization post-treatment.
• Current heparin reversal agent, protamine sulfate, has limitations including side effects and ineffectiveness against LMWH.
• Heparin use, especially in dialysis, is linked to severe adverse events like heparin-induced thrombocytopenia (HIT).

Purpose of the Study:

• To develop novel biocompatible macroporous cryogels for efficient heparin neutralization.
• To evaluate the efficacy of these cryogels against both UFH and LMWH.
• To explore the potential of these cryogels as a safer alternative to protamine sulfate.

Main Methods:

• Synthesis and characterization of macroporous cryogels based on poly(2-hydroxyethyl methacrylate) (pHEMA) and L-lysine.
• Assessment of the cryogels' filtering capabilities.
• Evaluation of the cryogels' heparin neutralization performance for UFH and LMWH.

Main Results:

• The synthesized pHEMA-L-lysine cryogels demonstrated strong filtering capabilities.
• These cryogels exhibited remarkable neutralization performance against both UFH and LMWH.
• The materials are biocompatible, suggesting suitability for blood-contact applications.

Conclusions:

• Biocompatible macroporous cryogels offer a promising new approach for heparin neutralization.
• These cryogels could be utilized in developing advanced filtering devices for rapid heparin reversal.
• This technology has the potential to enhance patient safety by mitigating risks associated with heparin therapy and its reversal.